Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (211-220 of 391) with videos related to

Pageof 40
Sort By:
Annals of the Rheumatic Diseases|August 8, 2020
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialJames R Seibold, Toby M Maher, Kristin B Highland, et al.
The Lancet. Respiratory Medicine|December 3, 2014
Combination therapy: the future of management for idiopathic pulmonary fibrosis?Wim A Wuyts, Katerina M Antoniou, Keren Borensztajn, et al.
Respirology (Carlton, Vic.)|January 4, 2012
Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumoniaTamera J Corte, Stephen J Wort, Peter S MacDonald, et al.
Journal of Scleroderma and Related Disorders|October 10, 2022
Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomographyDinesh Khanna, Oliver Distler, Vincent Cottin, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trialJustin M Oldham, Arata Azuma, Michael Kreuter, et al.
Thorax|May 5, 2012
The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaireAmit S Patel, Richard J Siegert, Katherine Brignall, et al.
American Journal of Respiratory and Critical Care Medicine|March 6, 2010
Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosisToby M Maher, Iona C Evans, Stephen E Bottoms, et al.
Annals of the American Thoracic Society|April 6, 2019
Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment InitiationToby M Maher, Lisa H Lancaster, Stéphane Jouneau, et al.
Journal of Clinical Epidemiology|May 26, 2015
Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung diseaseAmit S Patel, Richard J Siegert, Sabrina Bajwah, et al.
ERJ Open Research|December 8, 2017
Towards a global initiative for fibrosis treatment (GIFT)Maria Molina-Molina, Alvar Agusti, Bruno Crestani, et al.
Pageof 40

Showing results (211-220 of 391) with videos related to

Sort By:
Pageof 40
Annals of the Rheumatic Diseases|August 8, 2020
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialJames R Seibold, Toby M Maher, Kristin B Highland, et al.
The Lancet. Respiratory Medicine|December 3, 2014
Combination therapy: the future of management for idiopathic pulmonary fibrosis?Wim A Wuyts, Katerina M Antoniou, Keren Borensztajn, et al.
Respirology (Carlton, Vic.)|January 4, 2012
Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumoniaTamera J Corte, Stephen J Wort, Peter S MacDonald, et al.
Journal of Scleroderma and Related Disorders|October 10, 2022
Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomographyDinesh Khanna, Oliver Distler, Vincent Cottin, et al.
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trialJustin M Oldham, Arata Azuma, Michael Kreuter, et al.
Thorax|May 5, 2012
The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaireAmit S Patel, Richard J Siegert, Katherine Brignall, et al.
American Journal of Respiratory and Critical Care Medicine|March 6, 2010
Diminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosisToby M Maher, Iona C Evans, Stephen E Bottoms, et al.
Annals of the American Thoracic Society|April 6, 2019
Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment InitiationToby M Maher, Lisa H Lancaster, Stéphane Jouneau, et al.
Journal of Clinical Epidemiology|May 26, 2015
Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung diseaseAmit S Patel, Richard J Siegert, Sabrina Bajwah, et al.
ERJ Open Research|December 8, 2017
Towards a global initiative for fibrosis treatment (GIFT)Maria Molina-Molina, Alvar Agusti, Bruno Crestani, et al.
Pageof 40